Please log in to get access to this content
Dr. Laura Locati comments on the LIBRETTO-531 study of selpercatinib in previously untreated RET-mutant medullary thyroid carcinoma, which has provided a new treatment option for this patient population.
Speaker
- Dr. Laura Locati
University of Pavia, Italy